/
CRNX
$36.94+$0.24 (+0.65%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.9B
105M shares
52-week range
$25.83 – $57.99
35% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$17.02
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $1.2M | $71.0K | $1.1M | $4.7M | $4.0M | $1.0M | $7.7M |
| Cost of revenue | $24.5M | $1.1M | $57.0M | $0 | $0 | $0 | $0 | $1.1M |
| Gross profit | −$22.1M | $80.0K | −$56.9M | $1.1M | $4.7M | $4.0M | $1.0M | $6.6M |
| Gross margin | -908.2% | 6.7% | -80178.9% | 100.0% | 100.0% | 100.0% | 100.0% | 86.0% |
| R&D | $24.5M | $41.5M | $57.6M | $84.3M | $130.2M | $168.5M | $240.2M | $332.1M |
| Operating income | −$28.7M | −$53.8M | −$75.0M | −$107.7M | −$167.9M | −$222.6M | −$338.9M | −$516.8M |
| EBITDA | −$28.2M | −$49.3M | −$74.0M | −$106.7M | −$162.9M | −$213.4M | −$295.6M | −$461.2M |
| Net income | −$27.1M | −$49.5M | −$73.8M | −$107.6M | −$163.9M | −$214.5M | −$298.4M | −$465.3M |
| Net margin | -1116.8% | -4152.1% | -103960.6% | -9985.3% | -3460.4% | -5345.9% | -28720.7% | -6046.2% |
| EPS (diluted) | -2.23 | -2.05 | -2.42 | -2.80 | -3.15 | -3.69 | -3.69 | -4.95 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $68M | $-4.80 | $-5.22–$-4.09 | 10 |
| 2027 | $173M | $-4.21 | $-4.72–$-3.41 | 9 |
| 2028 | $420M | $-2.28 | $-3.42–$-0.71 | 5 |
| 2029 | $916M | $0.98 | $0.67–$1.23 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
www.crinetics.com- Employees
- 594
- IPO / List date
- Jul 18, 2018
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CRNX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CRNX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CRNX yet.
